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Summary
In the course of screening for new small-molecule
modulators of cell motility, we discovered that quino-
carmycin (also known as quinocarcin) analog DX-52-1
is an inhibitor of epithelial cell migration. While it has
been assumed that the main target of DX-52-1 is DNA,
we identified and confirmed radixin as the relevant
molecular target of DX-52-1 in the cell. Radixin is a
member of the ezrin/radixin/moesin family of mem-
brane-actin cytoskeleton linker proteins that also par-
ticipate insignal transductionpathways.DX-52-1binds
specifically and covalently to the C-terminal region of
radixin, which contains the domain that interacts with
actin filaments. Overexpression of radixin in cells
abrogates their sensitivity to DX-52-1’s antimigratory
activity. Small interfering RNA-mediated silencing of
radixin expression reduces the rate of cell migration.
Finally, we found that DX-52-1 disrupts radixin’s ability
to interact with both actin and the cell adhesion mole-
cule CD44.
Introduction
Cell migration involves regulated actin cytoskeletal
assembly and membrane protrusion, cell substratum
adhesion for traction, actin filament disassembly behind
the cell’s leading edge, cell body translocation, and
finally detachment from the substratum and retraction
of the trailing edge of the cell (for reviews, see [1–14]).
Changes in the state of the actin cytoskeleton and its
coupling to the membrane and extracellular matrix are
controlled by a large number of proteins, from effectors
of signal transduction to actin binding proteins that
determine the structure and function of the cytoskele-
ton. In an effort to better understand the molecular basis
of cell motility, we have been screening small organic
molecules for agents that affect cell migration.
We have adapted a rapid scratch-wounding assay for
high-throughput screening to a cell culture system utiliz-
ing Madin-Darby canine kidney (MDCK) epithelial cells
[15]. We previously found that wound closure in con-
fluent monolayers of MDCK cells depends upon the
*Correspondence: gabriel.fenteany@uconn.educollective active migration of multiple rows of cells from
the wound’s edge in a pathway involving phosphoinosi-
tides and Rac [16, 17], a member of the Rho family of
small GTPases and a key regulator of cytoskeletal
dynamics and cell motility (for reviews, see [18–21]). Up-
stream signaling to Rac in this system appears to be
mediated by glycogen synthase kinase 3 [22] and the
small GTPase ADP ribosylation factor 6 [23]. c-Jun
N-terminal kinase is also required for MDCK cell sheet
migration [24], putatively lying downstream of Rac, as
in other systems (for a review, see [20]). Using the wound
closure assay, we have identified a number of new inhib-
itors of cell migration, including locostatin, whose
molecular target, Raf kinase inhibitor protein, we have
implicated by multiple approaches in the positive con-
trol of epithelial cell migration [15, 25]. More recently,
we have discovered a number of other inhibitors of cell
motility, including quinocarmycin analog DX-52-1, which
we report on here. We identified DX-52-1 as a potent
inhibitor of cell migration and wound closure from the
National Cancer Society (NCI) Diversity Set, wherein it
is designated NSC 607097.
The natural product quinocarmycin (also known as
quinocarcin, DC-52-1, or KW-2152) and its semisyn-
thetic derivative DX-52-1 are known to have antitumor
activity in a number of cancer models [26–36]. These
compounds are characterized by a tetrahydroisoquino-
line skeleton, as are the saframycins, ecteinascidin 743,
and phthalascidin (for a review, see [37]). Quinocarmycin
has been shown to possess DNA-damaging activity
[27, 32, 38–40], and it has been suggested that DX-52-1
may alkylate DNA [38]. We believed, however, that alter-
native targets were likely to explain the antimigratory
activity of DX-52-1, as other DNA-alkylating agents such
as mitomycin C do not inhibit wound closure in MDCK
cell monolayers [17]. DX-52-1 has also been reported
to inhibit the hypoxia-inducible factor 1 transcriptional
activation pathway, although the direct molecular target
in this pathway has not been identified [41].
We synthesized a biotinylated derivative of DX-52-1
and found that it retained a sufficient amount of the anti-
migratory activity of the original free, nonbiotinylated
DX-52-1 to justify pursuit of the compound’s molecular
target in the cell. Using this biotinylated DX-52-1, we dis-
covered specific and covalent binding to an approxi-
mately 80 kDa protein that we subsequently purified
and identified as radixin, a nonenzymatic, membrane-
associated, actin binding protein [42].
Radixin is a member of the ezrin/radixin/moesin (ERM)
family of membrane-cytoskeleton linkers that are impor-
tant for organization of the membrane-associated corti-
cal actin cytoskeleton, cell migration, adhesion, and
proliferation (for reviews, see [43–46]). ERM proteins
are present in actin-rich cell surface structures such as
cell adhesion sites, membrane ruffles, filopodia, uro-
pods, microvilli, retraction fibers, and the cleavage fur-
row of dividing cells. In addition, ERM proteins play roles
in signal transduction, such as signaling through Rho
family small GTPases, by recruiting specific regulatory
molecules (for reviews, see [43–46]). They may also have
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tive of Quinocarmycin Analog DX-52-1 and
Putative Mechanism of Action for Modifica-
tion of Radixin by DX-52-1
(A) Quinocarmycin (also known as quinocar-
cin; 4) was converted to DX-52-1 (1) by hy-
drocyanation. Biotinylated DX-52-1 (3) was
prepared by EDC-mediated coupling of 1 to
N-hydroxysuccinimide to yield the ester 2,
which was reacted with (+)-biotin-PEO-
amine with spacer arm length of 22.9 A˚ to
provide 3.
(B) Putative mechanism of action for modifi-
cation of radixin by DX-52-1. Decyanation of
DX-52-1 (1) in the cell generates 5. After ini-
tial recognition, a specific nucleophilic amino
acid residue(s) (Nu) reacts with the electro-
philic iminium ion of 5, as indicated, to
form the covalent complex 6.roles in cancer progression; the ERM-related protein
merlin functions as a tumor suppressor whose mutation
underlies neurofibromatosis type 2 (for a review, see
[47]). DX-52-1 binds to the C-terminal region of radixin,
which contains its actin binding domain. We confirmed
radixin as a relevant cellular protein target of DX-52-1,
first by overexpressing radixin in cells and observing
a loss of the cells’ sensitivity to DX-52-1’s antimigratory
activity, and then by RNA interference (RNAi)-based si-
lencing of radixin expression, which resulted in delayed
cell migration. Modification of radixin by DX-52-1 dis-
rupts the interaction of radixin with actin and the cell
adhesion molecule CD44, which may account for DX-
52-1’s ability to inhibit epithelial cell migration.Results
Screening for Inhibitors of Wound Closure and
Identification of Quinocarmycin Analog DX-52-1
We screened over 10,000 small molecules from a variety
of sources, including the NCI Diversity Set, synthetic
organic molecules synthesized in our lab, and those
donatedbycolleagues. We identified sevenhighly potent
inhibitors of cell migration with clear subtoxic antimigra-
tory activity down to 500 nM or lower concentrations in
the wound closure assay. One of these compounds, qui-
nocarmycin analog DX-52-1 (1 in Figure 1), has an IC50
value of 140 nM (Figure 2). This compound has a drug-
like dose-dependent inhibitory profile and a favorableFigure 2. DX-52-1 Potently Inhibits Wound
Closure in MDCK Cell Monolayers
(A) Phase contrast images taken as a func-
tion of time after treatment with 0.01% (v/v)
DMSO or 300 nM DX-52-1 (treatment starting
at 30 min before wounding, as in all wound-
ing experiments). The scale bar represents
250 mm.
(B) Time course of wound closure after treat-
ment with 0.01% DMSO (n = 15 wounded
monolayers in separate wells); 25 nM DX-
52-1 (n = 15); 50 nM DX-52-1 (n = 14); 100
nM DX-52-1 (n = 15); 200 nM DX-52-1 (n =
15); 300 nM DX-52-1 (n = 15); 400 nM DX-
52-1 (n = 15); 500 nM DX-52-1 (n = 6). Final
DMSO carrier solvent concentration was
0.01% for each treatment. The wound clo-
sure assays were conducted as previously
described [15]. Data are mean 6 SEM. The
calculated IC50 value for inhibition of wound
closure at 24 hr by DX-52-1 is 140 nM.
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mum inhibitory concentration of 50 nM (unpaired two-
tailed Student’s t test for percent wound closure at 24
hr for 50 nM DX-52-1 versus 0.01% dimethyl sulfoxide
[DMSO] carrier solvent control for data in Figure 2, p =
0.006) and a minimum lethal concentration of 600 nM.
We ruled out that DX-52-1 inhibits cell migration by act-
ing as a direct inhibitor of actin filament assembly. Using
pyrene-labeled actin in a standard fluorescence-based
in vitro assay [48, 49], we found that DX-52-1 did not
affect actin polymerization (see Figure S1 in the Supple-
mental Data available with this article online).
DX-52-1, or 7-cyanoquinocarcinol, is the product of
hydrocyanation of the natural product quinocarmycin
(4 in Figure 1). Quinocarmycin itself had only very weak
subtoxic activity at 400 and 500 nM (inhibiting wound
closure at 24 hr by only 22% at 500 nM, relative to paral-
lel controls, compared to 96% inhibition for DX-52-1 at
the same concentration and time point). Quinocarmycin
had no activity at all at 300 nM and lower concentrations.
At 600 nM and above, quinocarmycin was cytotoxic with
long-term exposure. Saframycin A, which possesses the
same tetrahydroisoquinoline skeleton as quinocarmycin
and DX-52-1, is toxic down to 10 nM but does not appear
to have any subtoxic activity below that concentration.
Synthesis of Biotinylated DX-52-1
We prepared a biotinylated derivative of DX-52-1 (3 in
Figure 1) via the synthetic route shown in Figure 1A.
The structure was confirmed by nuclear magnetic reso-
nance (NMR) and mass spectrometry (MS). This com-
pound and the precursor ester 2 also inhibit wound clo-
sure, although not as potently as free nonbiotinylated
DX-52-1, with IC50 values of 1.3 mM for 2 and 2.4 mM
for biotinylated DX-52-1 (11% and 6% of the potency
of nonbiotinylated DX-52-1, respectively). Nevertheless,
this level of activity proved sufficient to purify DX-52-1
binding proteins (DBPs).
Isolation and Identification of DBPs
We observed four DBP bands at w35, w55, w80, and
w120 kDa when live MDCK cells were first treated
with biotinylated DX-52-1, the cells then lysed, and the
resulting whole-cell extracts analyzed for biotinylated
DX-52-1 binding activity (Figure 3A). The binding to all
the DBPs was specific and saturable, as simultaneous
addition of excess nonbiotinylated DX-52-1 completely
competed away biotinylated DX-52-1 binding (Figure 3A,
lane 7). The w80 kDa DBP is by far the most intensely
labeled, and is modified at lower concentrations of
biotinylated DX-52-1 than the other DBPs. We found
similar labeling patterns when we incubated whole-cell
extracts from nontreated cells with biotinylated DX-52-
1, although there also appeared some other nonspecific
binding (data not shown); the DBPs are thus able to
react with biotinylated DX-52-1 both in vivo and in vitro.
Because in each case the DX-52-1 binding activity
was visualized after adding sodium dodecyl sulfate
(SDS) sample buffer, boiling, and SDS-polyacrylamide
gel electrophoresis (PAGE), the interactions between
DX-52-1 and the DBPs appear stable and covalent.
Presumably, target alkylation occurs by reaction of a
nucleophilic residue on each DBP with the electrophilic
iminium ion 5 that forms upon loss of cyanide (CN2) fromDX-52-1 (Figure 1B). The formation of the reactive inter-
mediate 5 has previously been proposed in the context
of DNA alkylation [38].
Since thew80 kDa DBP was the most strongly labeled
by biotinylated DX-52-1, we purified thew80 kDa DBP on
the basis of its affinity for biotinylated DX-52-1. Upon mi-
crocapillary high-performance liquid chromatography-
tandem mass spectrometry (LC-MS/MS) of tryptic frag-
ments resulting from the w80 kDa DBP, two individual
proteins were identified: radixin, a membrane-cytoskele-
ton linker protein, and heat shock protein 70 (Hsp70),
a ubiquitous molecular chaperone.
We confirmed that radixin is a major target of DX-52-1
by immunoprecipitation of whole-cell extracts prepared
from biotinylated DX-52-1-treated live cells with an anti-
radixin antibody and then detection of the biotinylated
DX-52-1 binding activity (Figure 3B). We then obtained
and used recombinant radixin and Hsp70 proteins for
additional DX-52-1 binding and other in vitro experi-
ments. We found that Hsp70 only bound DX-52-1 very
slowly in a noncompetable and nonspecific manner (see
Figure S2). In addition, DX-52-1 did not affect Hsp70
ATPase activity in vitro (see Figure S3). Furthermore,
we found that treatment of MDCK cells with quercetin
and KNK437, inhibitors of Hsp70 expression, had little
or no effect on wound closure (see Figure S4).
In contrast, recombinant radixin bound biotinylated
DX-52-1 rapidly and specifically (Figure 3C). Quinocar-
mycin, the parent natural product that only has very little
antimigratory activity, competed only barely if at all with
biotinylated DX-52-1 for binding to the DBPs, particu-
larly radixin and the w120 kDa DBP (see Figure S5).
Using radixin truncates described previously [50, 51],
we found that DX-52-1 binds a C-terminal domain frag-
ment of radixin but not an N-terminal domain fragment
(Figure 3C). We therefore sought to determine whether
inhibition of radixin could explain the antimigratory
activity of DX-52-1 and pursue the functional conse-
quences of the specific reaction of radixin with DX-52-1.
Confirmation of Radixin as a Relevant Target
of DX-52-1 in the Cell
We transfected constructs containing hemagglutinin
(HA)-tagged radixin or green fluorescent protein (GFP)-
tagged radixin into MDCK cells, selected for stably ex-
pressing cells and isolated individual cell lines. Observa-
tion of the cells by fluorescence microscopy indicates
that the majority of cells in each population express the
transgene, although there is some heterogeneity in ex-
pression (see Figure S6). We calculated from the inten-
sity of bands on Western blots that the HA-radixin trans-
gene was expressed at w103% and the GFP-radixin
transgene at w95% that of endogenous radixin, for an
approximate doubling of total radixin levels in the overall
cell population in each case. We then tested the effect of
DX-52-1 on wound closure in confluent monolayers of
these cells. In support of the notion that radixin is a rel-
evant cellular protein target of DX-52-1, both HA-radi-
xin- and GFP-radixin-expressing cells were insensitive
to DX-52-1’s antimigratory activity at a concentration
that normally strongly inhibits wound closure (Figure 4;
compare to Figure 2). With both HA-radixin- and GFP-
radixin-expressing cell lines, however, DX-52-1 still
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(A) DX-52-1 binds several proteins to varying degrees in live cells.
Confluent MDCK cell cultures were incubated for 10 hr with (1)
0.05% DMSO as negative control; (2) 100 nM biotinylated DX-52-1;
(3) 200 nM biotinylated DX-52-1; (4) 500 nM biotinylated DX-52-1;
(5) 1 mM biotinylated DX-52-1; (6) 5 mM biotinylated DX-52-1; (7) 500
nM biotinylated DX-52-1 plus 25 mM free, nonbiotinylated DX-52-1
competitor added simultaneously. Final DMSO concentration was
0.05% for each treatment. Cells were lysed after treatment and
whole-cell extracts were subjected to SDS-PAGE, followed by blot-
ting to PVDF and chemiluminescent detection using streptavidin-
HRP to visualize in vivo biotinylated proteins. Similar results were
obtained when whole-cell extracts from nontreated cells were incu-
bated with biotinylated DX-52-1. The primary DBP (w80 kDa) was
purified and found to contain two proteins, radixin and Hsp70, by tan-
dem MS. Hsp70 was subsequently ruled out as a relevant DX-52-1
target (see text).
(B) Anti-radixin antibody immunoprecipitates radixin with covalently
bound biotinylated DX-52-1 from treated cells. Live MDCK cells were
treated with biotinylated DX-52-1 or carrier solvent alone, lysed, and
immunoprecipitated with anti-radixin antibody. After SDS-PAGE and
transfer to PVDF, the blot was probed with streptavidin-HRP,
followed by chemiluminescent detection. Lanes show biotinylated
radixin immunoprecipitated from cells treated with (1) 0.05%
DMSO as negative control; (2) 10 mM biotinylated DX-52-1. Lane 3becomes cytotoxic with long-term exposure at the same
higher concentrations as with normal cells.
In order to test whether loss of drug sensitivity with
overexpression of radixin is specific to DX-52-1 and not
just a general effect, we examined the response of
radixin-overexpressing cells to locostatin, a cell migra-
tion inhibitor that is unrelated to DX-52-1 and targets
Raf kinase inhibitor protein [15, 25]. We found that
overexpression of radixin did not affect the sensitivity
of the cells to locostatin’s antimigratory activity (see
Figure S7), which was similar to that of normal MDCK
cells [15].
RNAi-Based Silencing of Radixin Expression
We prepared MDCK cells stably expressing a radixin-
specific siRNA and control cells stably expressing an
inert siRNA. The efficiency of silencing of radixin expres-
sion was >90% by Western blot analysis (Figure 5A).
Wound closure in confluent monolayers of radixin
knockdown cells progressed more slowly than with con-
trol cells, demonstrating a reduced rate of cell migration
with radixin silencing (Figure 5B). We found that radixin
shows a separate Western blot of an equivalent loading as in lane 2
but probed with anti-radixin antibody.
(C) DX-52-1 binds the C-terminal region of recombinant radixin. Fol-
lowing incubation with biotinylated DX-52-1 in the presence or ab-
sence of excess nonbiotinylated competitor DX-52-1, recombinant
protein was subjected to SDS-PAGE and Western blot analysis
with streptavidin-HRP as in (A) and (B). Lanes (1) full-length radixin
with 10 mM biotinylated DX-52-1; (2) full-length radixin with 10 mM
biotinylated DX-52-1 plus 500 mM nonbiotinylated DX-52-1 com-
petitor; (3) N-terminal domain fragment of radixin with 10 mM bio-
tinylated DX-52-1; (4) N-terminal domain fragment of radixin with
10 mM biotinylated DX-52-1 plus 500 mM nonbiotinylated DX-52-1;
(5) C-terminal domain fragment of radixin with 10 mM biotinylated
DX-52-1; (6) C-terminal domain fragment of radixin with 10 mM bioti-
nylated DX-52-1 plus 500 mM nonbiotinylated DX-52-1. The N-termi-
nal domain fragment corresponds to amino acids 1–318 of murine
radixin, and the C-terminal domain fragment consists of amino acids
319–583 [50, 51]. All proteins in this experiment were expressed as
GST fusions, and the GST moiety was subsequently cleaved off.
(D) Coomassie blue-stained gel of equivalent sample loadings in the
same order as in (C).
Figure 4. Overexpression of Radixin in Cells Abrogates the Inhibi-
tory Effect of DX-52-1 on Cell Migration
Time course of wound closure in stable HA-radixin- and GFP-radi-
xin-expressing MDCK cell monolayers after the indicated treat-
ments. Assays were conducted as in Figure 2. Data are mean 6
SEM. See Figure S6 for corresponding microscope images. Al-
though overexpression of radixin makes the cells insensitive to
the subtoxic antimigratory activity of DX-52-1, the cells are still as
sensitive to the cytotoxic effects of DX-52-1 at higher concentra-
tions with long-term exposure as normal cells, implying that toxicity
is mediated by secondary targets, protein or DNA, and not radixin.
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with lower concentrations resulting in only weak inhibi-
tion of wound closure rates below the already reduced
rates of control knockdown cells (data not shown).
Effect of DX-52-1 on Interaction of Radixin
with ERM Binding Proteins
It has been shown previously that ezrin adsorbed onto
plastic in a solid phase binding assay exhibits filamen-
tous actin (F-actin) binding properties characteristic of
an active and not ‘‘dormant’’ state, and radixin binds
actin similarly in this assay [52, 53]. Furthermore, ezrin
binds monomeric actin (G-actin) in this system as well
[52]. In other assays, although enhanced by positive reg-
ulators such as phosphoinositides, association of ERM
proteins with ERM binding proteins still occurs in the
absence of activation [53–55].
Using first the solid phase assay, we found that bind-
ing of radixin to F-actin is disrupted by DX-52-1 (Fig-
ure 6A). We then employed a pull-down assay and found
that the interaction of radixin with F-actin in whole-cell
extracts is inhibited by DX-52-1 (Figure 6B). In addition,
DX-52-1 disrupts the interaction of radixin with G-actin
in the solid phase assay (see Figure S8). Because of the
high amounts of protein used in these assays and the
following assays to facilitate detection, higher concen-
trations of DX-52-1 were used than in the cellular assays.
We investigated the ability of DX-52-1 to affect inter-
actions of radixin with other known ERM binding pro-
teins, using pull-down assays similar to those described
previously [53–55]. We found that binding of radixin to
CD44 is also inhibited by DX-52-1 (Figure 7). However,
Figure 5. RNAi-Based Silencing of Radixin Expression Results in
a Decreased Rate of Cell Migration
(A) Western blots of total protein from control cells stably express-
ing an inert siRNA and radixin knockdown MDCK cells stably ex-
pressing a radixin-specific siRNA probed with anti-radixin and
anti-actin antibodies demonstrating knockdown of radixin.
(B) Time course of wound closure in confluent monolayers of con-
trol and radixin knockdown MDCK cells.DX-52-1 does not appear to affect the interaction of
radixin with ERM binding phosphoprotein 50 (EBP50),
also known as Na+/H+ exchanger regulatory factor (see
Figure S9).
Discussion
The parent natural product, quinocarmycin, becomes
cytotoxic at the same concentrations as DX-52-1, but
it has little of the subtoxic antimigratory activity of
DX-52-1. It is relevant to note that, unlike the cyano de-
rivative DX-52-1 [56, 57], quinocarmycin and the related
tetrazomine are capable of O2-dependent cleavage of
DNA by an alkylation-independent mechanism involving
generation of superoxide ion, which dominates under
aerobic conditions [56–58]. It is therefore possible that
quinocarmycin is cytotoxic but has little subtoxic activ-
ity by virtue of its participation in an aerobic redox
cycling pathway. Because DX-52-1 is not capable of
Figure 6. Interaction of Radixin with Actin Is Disrupted by DX-52-1
(A) DX-52-1 inhibits binding of radixin and F-actin in vitro in a solid
phase binding assay. GST-radixin (2 mg per well adsorbed onto
high protein binding capacity 96-well plates) was preincubated
with DX-52-1 or carrier solvent and then allowed to bind phalloidin-
stabilized F-actin added in solution (40 mg/ml actin) in F-actin
buffer. Following incubation and washing, protein complexes
were dissociated with SDS. The sample was then subjected to
SDS-PAGE and Western blot analysis with anti-actin antibody.
For a negative control, GST alone (2 mg per well) was used as above
instead of GST-radixin. Lanes show actin bound to (1) GST alone;
(2) GST-radixin with 1% DMSO; (3) GST-radixin with 1 mM DX-52-1;
(4) GST-radixin with 5 mM DX-52-1; (5) GST-radixin with 10 mM
DX-52-1. Similar results were found with baculovirally expressed
nonfusion radixin protein.
(B) DX-52-1 inhibits binding of radixin and F-actin in whole-cell ex-
tracts. MDCK cell extracts in F-actin buffer containing phalloidin
were subjected to pull-down with 10 mg GST-radixin (or 10 mg GST
as a negative control) immobilized onto glutathione-agarose beads
(and preincubated with DX-52-1 or carrier solvent prior to pull-
down), followed by SDS-PAGE and Western blot analysis with anti-
actin antibody. Lane 1 shows unmanipulated whole-cell extracts as
a positive control. Lanes 2–6 show actin pulled down from whole-
cell extracts by (2) GST alone; (3) GST-radixin with 1% DMSO;
(4) GST-radixin with 1 mM DX-52-1; (5) GST-radixin with 5 mM
DX-52-1; (6) GST-radixin with 10 mM DX-52-1.
(C) Loading control for lanes 1–6 in (B) showing amount of radixin
present (the blot in [B] was stripped and reprobed with anti-radixin
antibody).
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DNA [56, 57], it is probable that its primary mode of
reactivity is the alkylation of cellular targets.
The likely mechanism of action for modification of
DBPs by DX-52-1 is similar to that proposed for reaction
of the quinocarmycin iminium ion 5 with DNA [38], ex-
cept that, in the present case, the small molecule reacts
with nucleophilic amino acid side chains rather than
guanine residues of DNA (see Figure 1B). While radixin
is most strongly labeled by biotinylated DX-52-1, we
are also presently in the process of purifying the other
secondary DBPs that show up only with higher concen-
trations of biotinylated DX-52-1.
Radixin, ezrin, and moesin are nonenzymatic mem-
brane-cytoskeleton linkers whose functions have been
implicated in a range of processes, particularly at actin-
rich cell surface structures (for reviews, see [43–47]). To
our knowledge, DX-52-1 is the first inhibitor of radixin
discovered. DX-52-1 acts not by inhibiting an enzymatic
activity but by disrupting protein-protein interactions.
Although bioactive small molecules that inhibit protein-
protein interactions are much rarer than those that
target enzyme active sites (for reviews, see [59–70]), we
recently discovered that another cell migration inhibitor,
locostatin, which targets the signaling modulator Raf
kinase inhibitor protein, also acts by disrupting protein-
protein binding [25].
ERM proteins engage in a large number of protein-
protein and protein-endogenous small-molecule inter-
actions (for reviews, see [43–47]). One of their principal
functions is to link the cytoskeleton to the membrane
by simultaneously binding to actin filaments and mem-
brane proteins such as CD44, a cell adhesion molecule
that is a receptor for the extracellular matrix molecule
hyaluronan (for reviews, see [71–74]). We found that
the interaction of radixin with actin is disrupted when
DX-52-1 binds radixin (Figure 6; Figure S8). Furthermore,
the interaction of radixin with CD44 is also disrupted by
DX-52-1 (Figure 7).
In addition to CD44, radixin is known to bind CD43
and ICAM1-3 cell adhesion molecules (for reviews, see
[43–46]). ERM proteins can also interact indirectly with
membrane proteins via the PDZ protein-protein inter-
action domain-containing proteins EBP50 and E3KARP
(for reviews, see [43, 45–47]). Additional proteins from a
Figure 7. Interaction of Radixin with CD44 Is Disrupted by DX-52-1
One microgram of baculovirally expressed radixin, preincubated
with DX-52-1 or carrier solvent, was subjected to pull-down with
10 mg GST-CD44 (or 10 mg GST alone as a negative control) immo-
bilized onto glutathione-agarose beads, followed by SDS-PAGE
and Western blot analysis with anti-radixin antibody. Lane 1 con-
sists of radixin loaded directly as a positive control for efficacy of
probing the Western blot. Lanes 2–6 show radixin pulled down by
(2) GST alone; (3) GST-CD44 with 1% DMSO; (4) GST-CD44 with
1 mM DX-52-1; (5) GST-CD44 with 5 mM DX-52-1; (6) GST-CD44
with 10 mM DX-52-1.range of functional classes are known to bind ERM pro-
teins, including Dbl, a guanine nucleotide exchange fac-
tor that positively regulates Rho family small GTPases,
and Rho guanine nucleotide dissociation inhibitor, which
negatively regulates Rho proteins (for reviews, see
[43–47]). Phosphoinositides bind the N-terminal 4.1/
ERM (FERM) domain of ERM proteins and are involved
in their activation (for reviews, see [43–47]). ERM pro-
teins are also positively regulated by phosphorylation
of their C-terminal regions by kinases such as Rho ki-
nase, which is activated by Rho, and different isoforms
of protein kinase C (for reviews, see [43, 45–47]). While
we have not yet examined all of these interactions and
modifications, we observed no effect of DX-52-1 on
the ability of radixin to bind EBP50 (Figure S9).
DX-52-1 binds the C-terminal region of radixin (Fig-
ure 3C), while disrupting interactions of radixin with
both actin filaments (Figure 6) and CD44 (Figure 7). Be-
cause the interactions with actin and CD44 occur within
the C-terminal and N-terminal regions of radixin, respec-
tively, binding of DX-52-1 appears to affect protein-
protein interactions at both close range (e.g., through
direct steric interference or local allosteric effects) and
long range (e.g., through larger scale allosteric effects).
Activation of ERM proteins enhances their association
with ERM binding proteins and is thought to result
from release of an autoinhibitory intramolecular inter-
action between the N-terminal FERM domain and the
C-terminal actin binding domain (for reviews, see
[43–47]). It could be hypothesized that binding of
DX-52-1 promotes or favors the inactive, autoinhibited
conformation of radixin, thus preventing association of
the N-terminal FERM domain with CD44 and the C-ter-
minal actin binding domain with actin. However, such
a notion is not consistent with the result that the interac-
tion of radixin with EBP50, which also involves the FERM
domain, is unaffected by treatment with DX-52-1. There-
fore, modification of radixin by DX-52-1 does not simply
stabilize a closed, autoinhibited state of radixin. None-
theless, it is possible that the conformational state of
radixin upon binding of DX-52-1 partly mimics the inac-
tive state, allowing certain interactions but not others.
An alternative is that binding of DX-52-1 to the N-termi-
nal domain of radixin does occur also, but the binding is
either reversible or, if covalent and irreversible, only oc-
curs with full-length protein, because of differences in
organization of the N-terminal domain between full-
length radixin and the fragment. We are currently explor-
ing these possible models.
Significance
We show that quinocarmycin analog DX-52-1, whose
effects on the cell were previously assumed to be me-
diated by alkylation of DNA, also targets the mem-
brane-actin cytoskeleton linker and signaling protein
radixin. Modification of radixin by DX-52-1 appears to
explain at least part of the inhibitory effect of DX-52-1
on cell migration, as confirmed by both overexpres-
sion and siRNA-mediated silencing experiments.
DX-52-1 thus represents, to our knowledge, the first
known inhibitor of radixin, and it acts by disrupting
the interaction of radixin with both actin and the cell
adhesion protein CD44.
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Wound Closure Assay
MDCK cells were obtained from the American Type Culture Collec-
tion and cultured in growth medium (minimum essential medium
with 10% [v/v] newborn calf serum) and grown to confluence at
37C with 5% CO2 in a humidified tissue culture incubator. All exper-
iments were performed using early passages of MDCK cells from
frozen stock cultures stored in liquid N2. High-throughput wound
closure screens were carried out in 96-well tissue culture plates,
as previously described [15]. Compounds were initially screened in
triplicate at a concentration of 50 mM. ‘‘Hits’’ at 50 mM were then
rescreened at lower concentrations. Those with subtoxic inhibitory
activity down to%500 nM were tested again with larger sample sizes
over a range of concentrations to obtain dose-response profiles and
IC50 values.
Actin Purification, Labeling, and Polymerization
Actin was prepared from rabbit muscle acetone powder according to
published procedures [75, 76], with two additional rounds of poly-
merization-depolymerization. SDS-PAGE revealed a single band.
The purified actin was then labeled with N-(1-pyrene)iodoacetamide
(Invitrogen/Molecular Probes), and the resulting pyrene-labeled ac-
tin was used to assess the effect of DX-52-1 on the rate and extent of
actin polymerization, according to established procedures [48, 49].
Briefly, pyrene-labeled G-actin (50% labeled) was added to a final
concentration of 2 mM in ME buffer (50 mM MgCl2, 0.2 mM ethylene
glycol-bis(2-aminoethyl ether)-N,N,N0,N0-tetraacetic acid [EGTA]) in
the presence or absence of compound in a total volume of 100 ml.
After preincubation for 1 hr at 4C, polymerization was initiated by
addition of 2.5 ml 103 KMEI buffer (50 mM KCl, 1 mM MgCl2, 1 mM
EGTA, 10 mM imidazole [pH 7.0]) and measured by fluorescence
spectrophotometry (340 nm excitation/420 nm emission).
Preparation of Biotinylated DX-52-1 (3)
DX-52-1 (1) was prepared as previously described [77]. For syn-
thesis of 3, the biotinylated derivative of 1, a mixture of 1 (42.5 mg,
0.119 mmol, 1.0 eq), 1-ethyl-3-(3-dimethylaminopropyl)-carbodii-
mide hydrochloride (EDC, 34.1 mg, 0.178 mmol, 1.5 eq), and N-hy-
droxysuccinimide (34.1 mg, 0.298 mmol, 2.5 eq) in N,N-dimethylfor-
mamide (2.0 ml) was stirred at room temperature, under an N2
atmosphere for 24 hr. The reaction mixture was then poured into
a saturated aqueous NaHCO3 solution (2 ml), and the product was
extracted with ethyl acetate (3 3 4 ml). The organic phase was
sequentially washed with water (4 ml) and saturated aqueous NaCl
(4 ml), dried over Na2SO4, and then concentrated under reduced
pressure. The remaining residue was purified by flash chromatogra-
phy (silica gel, eluent: 7:3 dichloromethane/ethyl acetate) to provide
the ester 2 (38.1 mg) as a yellow oil. The identity of 2 was confirmed
by NMR and MS. 2 (28 mg, 0.062 mmol, 1.0 eq) was then dissolved in
methanol (1.5 ml), and (+)-biotin-PEO-amine with a 22.9 A˚ spacer
arm length (Molecular Biosciences; 52.0 mg, 0.124 mmol, 2.0 eq)
was added to the solution. Progress of this reaction was monitored
by thin layer chromatography. After stirring for 12 hr at room temper-
ature the solvent was evaporated under reduced pressure, and the
remaining residue was washed with ethyl acetate (23 3 ml) and dis-
solved in chloroform (1 ml). After concentration of this solution, the
residue was subjected to flash chromatography (silica gel, eluent:
8.8:1.2 dichloromethane/methanol) to provide 3 (17.8 mg, 20% over-
all yield from 1).
Characterization of Biotinylated DX-52-1 (3)
1H-NMR (400 MHz, CDCl3): d 1.23–1.58 (m, 6H), 1.50–1.80 (m, 2H),
1.99 (br s, 1H), 2.06–2.23 (m, 2H), 2.32–2.40 (m, 1H), 2.45–2.58 (m, in-
cluding s at 2.50 ppm, 4H), 2.63–2.76 (m, 2H), 2.80–2.90 (m, 1H),
3.02–3.15 (m, 2H), 3.25–3.75 (m, 21H), 3.79 (s, 3H), 3.96 (br d, J =
2.2 Hz, 2H), 4.18–4.26 (m, 1H), 5.39 (br s, 1H), 6.06 (br s, 1H), 6.68
(d, J = 7.7 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 7.12 (app t, J = 7.9 Hz,
1H), 7.32 (br t, 1 H); 13C-NMR (100.6 MHz, CDCl3): 175.70, 173.26,
163.98, 155.70, 136.77, 127.55, 122.17, 120.40, 118.08, 108.29,
70.37 (2C), 69.40 (3C), 68.89, 69.73, 69.12, 64.87, 61.65, 60.14,
57.90, 57.63, 57.42, 55.37, 55.24, 44.16, 41.72, 40.55, 39.12, 39.03,
35.55, 32.73, 31.84, 27.87, 27.67, 25.41. HRMS (ESI) (m/z): [M + H+]
calculated for C37H55N7O8S, 758.3904; found, 758.3911.Binding of Biotinylated DX-52-1 to Proteins
We initially performed experiments examining binding of biotiny-
lated DX-52-1 to proteins in live cells. MDCK cells were plated on
100 mm diameter tissue culture plates at an initial density of 5.0 3
106 cells/plate in growth medium. Seven plates of confluent MDCK
cell monolayers were incubated with a range of biotinylated DX-
52-1 concentrations for 10 hr, with or without 503 molar excess of
nonbiotinylated competitor DX-52-1 (or quinocarmycin) added
simultaneously. Cells were then washed twice with phosphate-
buffered saline (PBS) and lysed in ice-cold lysis buffer (20 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 2 mM ethylenediaminetetraacetic
acid [EDTA], 2 mM dithiothreitol [DTT], 0.5% [w/v] Triton X-100,
1 mg/ml leupeptin, 1 mg/ml pepstatin A, 0.1 mM phenylmethylsulfonyl
fluoride [PMSF], 0.1 mM benzamidine). After 30 min on ice, the plates
were scraped with cell scrapers. Samples were homogenized by
passing through a 27 gauge needle, transferred to new 1.5 ml tubes,
and centrifuged (15,000 3 g, 30 min, 4C). Supernatants were con-
centrated tow2 mg total protein/ml, as determined by the Bradford
assay [78], in Amicon centrifugal concentrators (Millipore) with a
molecular weight cutoff of 5,000 Da (4,000 3 g, 4C).
For detection of biotinylated DX-52-1 bound to proteins, equal
volumes of 23 SDS sample buffer were first added to each superna-
tant sample, and the samples were boiled for 5 min. In addition, the
pellet samples were separately resuspended in 23 SDS sample
buffer. After SDS-PAGE, the proteins were electrophoretically trans-
ferred to Immobilon polyvinylidene difluoride (PVDF) membranes
(Millipore). The resulting blots were blocked for 2 hr with 5% (w/v)
BSA in 1% (w/v) Tween 20/Tris-buffered saline (T-TBS), then incu-
bated with 1:1000 streptavidin-horseradish peroxidase (HRP) from
Sigma in T-TBS for 1 hr. Blots were washed four times (10 min
each) with T-TBS, and the biotinylated proteins were visualized
using the Amersham/GE Healthcare enhanced chemiluminescence
system.
We also examined binding of biotinylated DX-52-1 to proteins in
whole-cell extracts in vitro. The whole-cell extracts were prepared
as above in lysis buffer but from MDCK cells that had not been
treated with biotinylated DX-52-1. Extracts (50 ml of a w2 mg total
protein/ml solution) were then treated with biotinylated DX-52-1,
with or without addition of 503 molar excess of nonbiotinylated
competitor DX-52-1 at the same time as biotinylated DX-52-1. The
samples were incubated for 8 hr at 4C on a rotating wheel. Equal
volumes of 23 SDS sample buffer were then added to each sample.
The samples were boiled for 5 min, then subjected to SDS-PAGE,
blotted to PVDF, and probed with HRP-streptavidin as described
above.
Purification of the w80 kDa DBP
Two hundred confluent MDCK cell cultures on 100 mm diameter tis-
sue culture plates were treated with 10 mM biotinylated DX-52-1, and
whole-cell extracts were prepared as described above. All purifica-
tion steps were carried out at 4C. The ‘‘prelabeled’’ whole-cell ex-
tracts (w500 mg total protein) were initially fractionated by adding
ammonium sulfate (AS) sequentially to 20%, 40%, 60%, and finally
80% (w/v) saturation. Each pellet was resuspended in low-salt buffer
(20 mM bis-Tris [pH 7.0], 10 mM NaCl, 2 mM EDTA, 2 mM DTT,
1 mg/ml leupeptin, 1 mg/ml pepstatin A, 0.1 mM PMSF, 0.1 mM
benzamidine). The suspensions were dialyzed overnight against
the same buffer at 4C. Samples were then centrifuged in 50 ml poly-
carbonate tubes (15,000 3 g, 30 min, 4C) to remove precipitates
formed during dialysis.
The w80 kDa DBP precipitated in the 60% AS pellet, while the
w120 kDa DBP came out in the 40% AS pellet, based on detection
of DBPs by the procedure described earlier. The 60% AS pellet was
resuspended in low-salt buffer (w120 mg total protein) and loaded
onto a 5 ml HiTrap Q-sepharose anion exchange column (Amer-
sham), preequilibrated with low-salt buffer. After washing the col-
umn with 40 ml low-salt buffer, elution was achieved with a 60 ml lin-
ear gradient of 50–400 mM NaCl. The flowthrough and all fractions
were collected and resolved by SDS-PAGE, followed by detection
of DBPs.
Thew80 kDa DBP eluted around 100 mM NaCl. Fractions contain-
ing thew80 kDa DBP were combined and dialyzed overnight against
low-salt buffer. To preclear nonspecific agarose binding proteins,
an equal volume of agarose beads (MP Biomedical) was added as
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(1,000 3 g, 5 min, 4C). The supernatant was recovered, an equal
volume of streptavidin-agarose beads (Prozyme) was added as
a 1:1 slurry in low-salt buffer, and the sample was incubated for
2 hr at 4C on a rotating wheel. After centrifugation (1,000 3 g,
5 min, 4C), the beads and supernatant were separated by removing
the supernatant with a micropipet. The beads were washed exten-
sively with ice-cold PBS to remove unbound proteins, and elution
of bound proteins from the beads was achieved by heating in a min-
imal volume of 23 SDS sample buffer. Samples were boiled for 5 min
to release bound proteins, then subjected to SDS-PAGE and ana-
lyzed for DX-52-1 binding activity, with separate nonspecific protein
visualization of parallel gels by silver staining. In addition, the origi-
nal supernatant was also analyzed to determine the amount of
protein that remained unbound.
Protein Identification
To prepare for identification of w80 kDa DBP by LC-MS/MS, sam-
ples containing purified w80 kDa DBP were subjected to SDS-
PAGE, and the gels were stained with SYPRO Ruby dye according
to the manufacturer’s instructions (Invitrogen/Molecular Probes).
The band corresponding to the w80 kDa DBP was excised from
the stained gels, yielding a final total of w18 ng of the w80 kDa
DBP. Excised protein bands were subjected to in-gel reduction,
S-carboxyamidomethylation, and digestion with trypsin. Peptide
sequences were determined using a 75 mm reverse-phase micro-
column terminating in a PicoView nanoelectrospray source (New
Objective) directly coupled to an LTQ linear quadrupole ion trap
mass spectrometer (Thermo Electron), then analyzed as previously
described [25].
Immunoprecipitation of Radixin
Live MDCK cells were treated with biotinylated DX-52-1 for 10 hr and
lysed, as described earlier. The whole-cell extracts (500 ml of
a w4 mg total protein/ml solution) were precleared with 50 ml of
a 1:1 slurry of protein A-sepharose beads (Invitrogen/Zymed Labo-
ratories) in lysis buffer. Radixin was then immunoprecipitated with
a goat anti-human radixin polyclonal antibody (Santa Cruz Biotech-
nology, sc-6408). After SDS-PAGE and transfer to PVDF, biotiny-
lated protein was detected with streptavidin-HRP, as above.
Baculoviral Expression of Radixin
Murine radixin cDNA [79] in the pBluescript II SK(2) cloning vector
was amplified by the polymerase chain reaction with 50-ATAGC
GGCCGCATGCCGAAGCCAATCAATGTAAGA-30 and 50-ATAGGATC
CTCACATGGCTTCAAACTCATCGAT-30 as the forward and reverse
primers, respectively. The amplified product was subcloned into
the NotI and BamHI sites of baculovirus transfer vector pVL1392
(BD Biosciences Pharmingen), and the primary structure of the re-
sulting pVL1392-radixin construct was confirmed by restriction
enzyme digests and DNA sequencing.
Sf9 insect cells were cultured at 27C from cell stocks at 1–10 3
106 cells/ml in Sf-900 II serum-free medium (Invitrogen/GIBCO)
containing 100 units/ml penicillin, 0.1 mg/ml streptomycin, and
0.25 mg/ml amphotericin B (Sigma), with rotation at 250 rpm in
500 ml spinner flasks. Recombinant virus encoding radixin was gen-
erated and amplified according to the manufacturer’s instructions
(BaculoGold transfection kit, BD Biosciences Pharmingen). Briefly,
60 mm diameter tissue culture plates were seeded with 23 106 cells
and cotransfected with 0.5 mg linearized BaculoGold (modified
AcNPV) baculovirus DNA and 4 mg pVL1392-radixin complexed
with 2 ml transfection reagent. After incubation for 4 hr at 27C,
the medium was replaced. Five days after transfection, culture
supernatants were collected and first-passage recombinant virus
was isolated. Second-passage virus was expanded from the first-
passage stock and used at a multiplicity of infection of 0.1 for gen-
eration of high-titer third-passage viral stock. Successful transfec-
tion and virus production were monitored by observing arrest of
cell growth and/or cell death at later time points (4–5 days).
Purification of recombinant radixin was carried out as described
previously [54], with slight modification. Sf9 cells cultured in a 2 l
spinner flask were infected with recombinant virus for 72 hr at
28C, then harvested and lysed with 30 ml of a buffer consisting of
20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EGTA, 2 mM DTT,0.5% Triton X-100, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, 0.1 mM
PMSF, and 0.1 mM benzamidine. After homogenization and sonica-
tion, cell debris was removed by centrifugation (100,000 3 g, 1 hr,
4C). The supernatant was then loaded onto a 5 ml HiTrap heparin
column (Amersham) which had been preequilibrated with BV buffer
(10 mM HEPES [pH 7.5], 1 mM EGTA, 0.1 mM DTT). After washing the
column with BV buffer, elution was achieved with a linear gradient of
150–750 mM KCl. Radixin eluted around 300 mM KCl. The eluate was
dialyzed against BV buffer and then centrifuged (100,000 3 g, 1 hr,
4C). The sample was then loaded onto a preequilibrated (BV buffer)
5 ml HiTrap Q-sepharose anion exchange column (Amersham). After
washing the column with BV buffer, proteins were eluted with a linear
gradient of 0–200 mM KCl, and fractions were collected. The amount
and purity of the recombinant radixin were analyzed by absorbance
at 280 nm and SDS-PAGE. Fractions containing the highest amounts
of radixin, corresponding to elution around 50 mM KCl, were pooled
and dialyzed against BV buffer overnight at 4C before flash freezing
in liquid N2 and storage at 280
C.
Expression and Purification of Other Recombinant Proteins
GST fusions of full-length and N-terminal and C-terminal domain
fragments of murine radixin [51], the human cytoplasmic domain
of CD44 [80] and human EBP50 [81], in the pGEX-2T, pGEX-KG,
and pGEX-3X vectors, respectively, were expressed in BL21(DE3)-
pLysS Escherichia coli cells. Single bacterial colonies were used
to seed cultures in 500 ml of Luria-Bertani medium. After growing
the cells overnight, isopropyl-D-thiogalactopyranoside was added
to 0.2 mM, followed by incubation for 3 hr, and cells were then col-
lected by centrifugation (50003 g, 10 min). Bacterial pellets were re-
suspended in 25 ml ice-cold PBS containing 2 mM EDTA, 1 mM DTT,
1 mg/ml leupeptin, 1 mg/ml pepstatin A, 0.1 mM PMSF, and 0.1 mM
benzamidine. After sonication, the lysates were diluted to 50 ml in
PBS and centrifuged (15,0003 g, 30 min, 4C). The resulting super-
natants were mixed with 6 ml of a 1:1 slurry of glutathione-agarose
beads (Sigma) in PBS, and then incubated on a rotating wheel for
1 hr at 4C. Beads were washed four times with PBS, and GST-fusion
proteins were eluted with 10 mM reduced glutathione (Sigma) in
50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2.5 mM CaCl2, and 1 mM
DTT. His6-Hsp70 (bovine) in the pQE9 expression vector was ex-
pressed and purified on an Ni-nitrilotriacetic acid-agarose column
(Qiagen), as described previously [82].
Binding of DX-52-1 to Radixin Fragments
Following expression and purification, the GST moiety was cleaved
from the fusion proteins consisting of full-length radixin and N-termi-
nal and C-terminal domain fragments of radixin by treatment with
bovine thrombin (Sigma) for 24 hr at 4C. Each recombinant protein
(50 ml of 400 mg/ml solutions in a buffer of 20 mM Tris-HCl [pH 7.4],
150 mM NaCl, 2 mM EDTA, 2 mM DTT, 0.5% Triton X-100, 1 mg/ml
leupeptin, 1 mg/ml pepstatin A, 100 mM PMSF, and 100 mM benzami-
dine) was incubated with biotinylated DX-52-1, with or without 503
excess nonbiotinylated DX-52-1 competitor added simultaneously,
for 4 hr at 4C. After adding equal volumes of 23 SDS sample buffer,
samples were then subjected to SDS-PAGE, transferred to PVDF,
and detected with streptavidin-HRP, as described earlier.
Hsp70 Binding and ATPase Activity
His6-Hsp70 (50 ml of a 1.2 mg/ml solution in a buffer of 20 mM Tris-
HCl [pH 7.4], 150 mM NaCl, 2 mM EDTA, 2 mM DTT, 0.5% Triton
X-100, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, 100 mM PMSF, and
100 mM benzamidine) was incubated with biotinylated DX-52-1,
with or without 503 excess nonbiotinylated DX-52-1 competitor
added simultaneously, for 4 hr at 4C. This was followed by SDS-
PAGE, transfer to PVDF, and detection with streptavidin-HRP, as
above. Hsp70 ATPase activity, after preincubation of 250 mg/ml
His6-Hsp70 in the presence or absence of DX-52-1 for 4 hr at 4
C,
was assayed as previously described [83–85].
Stable Transfection of MDCK Cells
To prepare stable transfectants expressing HA-radixin, MDCK cells
were cotransfected at a 1:10 molar ratio with pSV2-Neo and a pMFG
retroviral vector containing cDNA for murine radixin tagged at its C
terminus with the HA epitope, as previously described [50]. GFP-
radixin-expressing MDCK cells were prepared by transfection with
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enhanced GFP (EGFP) in the pEGFP-N1 mammalian expression
vector. In both cases, transfection was mediated by lipofectamine
(Invitrogen/GIBCO), following the manufacturer’s instructions.
Selection and maintenance of stable transfectants were carried
out in growth medium with 500 mg/ml G418 sulfate (Geneticin)
from Invitrogen/GIBCO. Following serial dilution of HA-radixin-
expressing cells or fluorescence-activated cell sorting of GFP-radi-
xin-expressing cells, individual cell lines were isolated from tissue
culture plates containing cells at low density with sterile cloning
discs for expansion on new plates. Transgene expression was eval-
uated by GFP fluorescence or HA immunofluorescence, as well as
by Western blot analysis.
Fluorescence Observation of Cells
To visualize HA-radixin in cells, HA-radixin-expressing MDCK cells
were fixed with 3.7% formaldehyde in PBS, permeabilized with
0.5% Triton X-100, and immunostained for the HA epitope with
a mouse anti-HA monoclonal antibody (Santa Cruz Biotechnology,
sc-7392) and an Alexa Fluor 350-conjugated goat anti-mouse IgG
secondary antibody (Invitrogen/Molecular Probes, A-11068). Obser-
vation was by standard fluorescence microscopy. In many cases,
cells were costained for F-actin with 50 nM tetramethylrhodamine
isothiocyanate (TRITC)-labeled phalloidin (Sigma) to visualize gross
actin cytoskeletal structure and actin-rich cell boundaries. GFP-
radixin-expressing MDCK cells were observed both live and fixed,
the latter when covisualization of F-actin with TRITC-phalloidin
was desired.
siRNA-Mediated Silencing of Radixin Expression
Silencing of radixin expression was achieved using a small hairpin
RNA (shRNA) expression vector modified from that previously de-
scribed [22, 25]. Five potentially effective siRNA target sequences
corresponding to different parts of the coding regions of canine rad-
ixin, and not found elsewhere in the canine genome (including the
two other ERM proteins, ezrin and moesin), were identified with Am-
bion’s siRNA Target Finder algorithm. The siRNA target sequences
were synthesized as shRNAs and ligated into the shRNA expression
vector. The constructs were then separately transfected into MDCK
cells by lipofectamine-mediated transfection, according to the man-
ufacturer’s protocol (Invitrogen/GIBCO). Stable transfectants were
selected in growth medium with 100 mg/ml hygromycin B (A.G. Sci-
entific). Because the shRNA expression vector contains a GFP
expression cassette [25], GFP-positive cells were isolated by fluo-
rescence-activated cell sorter. Efficiency of knockdown was evalu-
ated by Western blot analysis. The best knockdown was achieved
with an siRNA corresponding to nucleotides 445–465 of canine rad-
ixin (GenBank accession number: XM857605). As a control for
the subsequent wound closure experiments, we used a cell line
expressing an siRNA corresponding to the coding region between
nucleotides 1553 and 1573 of canine radixin, which we found to
cause no change in radixin protein levels. Each cell line was main-
tained in growth medium containing 100 mg/ml hygromycin B.
Solid Phase Actin Binding
Recombinant radixin was assayed for actin binding in the presence
or absence of DX-52-1 using a solid phase binding assay described
previously [52]. Seventy-five microliters of GST-radixin (26.7 mg/ml),
baculovirally expressed radixin (26.7 mg/ml), or GST alone as a neg-
ative control (26.7 mg/ml) was coated onto separate wells (2 mg pro-
tein per well) of Nunc MaxiSorp 96-well ELISA plates (with high pro-
tein binding capacity) in F-actin buffer (10 mM HEPES [pH 7.0],
100 mM KCl, 2 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 0.5 mM
ATP). After incubation overnight at 37C, wells were washed with
F-actin buffer. Nonspecific binding sites were blocked with 2% (w/v)
bovine serum albumin. After washing wells again twice, DX-52-1
was added in 50 ml F-actin buffer. After incubation for 1 hr at room
temperature, F-actin stabilized with 10 mM phalloidin (Sigma) was
added to each radixin-coated well to a final concentration of 40
mg/ml actin. After another 1 hr incubation, wells were washed three
times to remove unbound actin, and protein complexes were disso-
ciated by adding 30 ml 23 SDS sample buffer to each well for 20 min
at 65C. Samples were transferred to 0.6 ml microcentrifuge tubes,
boiled for 5 min, and subjected to SDS-PAGE (12% gel). Sampleswere blotted to PVDF for Western blot analysis with a mouse anti-
actin monoclonal antibody (Sigma, A2066).
Experiments involving G-actin were done similarly to those with
F-actin above, except G-actin buffer (20 mM Tris-HCl [pH 8.0],
0.2 mM CaCl2, 0.5 mM DTT, 0.2 mM ATP, 0.005% NaN3) was used
instead of F-actin buffer and phalloidin was omitted in all steps.
Seventy-five microliters of GST-radixin (26.7 mg/ml), baculovirally
expressed radixin (26.7 mg/ml), or GST alone as a negative control
(26.7 mg/ml) in G-actin buffer was coated onto separate wells (2 mg
protein per well) of Nunc MaxiSorp 96-well plates, with incubation
overnight at 37C. Wells were washed with G-actin buffer, and resid-
ual binding sites were blocked with 2% BSA. Wells were washed
again twice and then DX-52-1 or DMSO carrier solvent was added
in 50 ml G-actin buffer. After incubation for 1 hr at room temperature,
G-actin was added to a final concentration of 80 mg/ml. After another
1 hr incubation, wells were washed three times, and bound G-actin
was solubilized in 30 ml 23 SDS sample buffer, followed by SDS-
PAGE and Western blot analysis with anti-actin antibody.
Pull-Down of F-Actin from MDCK Cell Extracts
with Recombinant Radixin
Following change of buffer to F-actin buffer, 10 mg GST-radixin or
10 mg GST alone as a negative control was immobilized onto gluta-
thione-agarose beads (25 ml of a 1:1 slurry in F-actin buffer), and DX-
52-1 or carrier solvent was added. After 30 min, whole-cell extracts
(w1 mg total protein in F-actin buffer with 0.1% Tween 20 and 10 mM
phalloidin) were added for a final volume of 100 ml. The beads were
incubated for 2 hr at 4C with gentle rocking, followed by three cy-
cles of washing in the same buffer to remove unbound proteins,
with centrifugation (500 3 g, 1 min) between each wash to collect
the beads. Bound proteins were eluted from the beads with 30 ml
23 SDS sample buffer. Following boiling, samples were subjected
to SDS-PAGE and Western blot analysis with anti-actin antibody.
Pull-Down of Recombinant Radixin with GST-CD44
or GST-EBP50
These assays were done similarly to those previously described
[53–55]. Ten micrograms of each GST-fusion protein or 10 mg GST
alone as a negative control was immobilized onto glutathione-
agarose beads (25 ml of a 1:1 slurry in PBS). Samples were then in-
cubated with 1 mg baculovirally expressed radixin (final volume of
100 ml in PBS with 0.1% Triton X-100) that had been preincubated
for 30 min with DX-52-1 or carrier solvent. After incubation for 2 hr
at 4C with gentle rocking, beads were washed three times in ice-
cold PBS with 0.02% Tween 20 to remove unbound proteins. Bound
proteins were eluted in 30 ml 23 SDS sample buffer, boiled, and then
subjected to SDS-PAGE and Western blot analysis with anti-radixin
antibody.
Supplemental Data
Supplemental Data include nine figures and are available at http://
www.chembiol.com/cgi/content/full/13/9/973/DC1/.
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